What is Enlitic?
Enlitic operates at the intersection of artificial intelligence and clinical diagnostics, providing sophisticated software-as-a-medical device (SaMD) solutions tailored for radiologists. The company is dedicated to enhancing diagnostic accuracy and operational efficiency, ensuring that its platforms meet rigorous regulatory and quality standards. By integrating advanced machine learning algorithms into clinical workflows, Enlitic empowers healthcare providers to improve patient outcomes through faster, more precise data analysis. Its market position is defined by a commitment to bridging the gap between complex medical data and actionable clinical insights, effectively transforming how radiology departments manage high-volume diagnostic tasks.
How much funding has Enlitic raised?
Enlitic has raised a total of $36.4M across 4 funding rounds:
Angel/Seed
$2M
Series A
$3M
Series B
$25M
Other Financing Round
$6.4M
Angel/Seed (2014): $2M with participation from Amplify.La Capital II and Data Collective
Series A (2015): $3M, investors not publicly disclosed
Series B (2019): $25M supported by Thorney Investment Group, Capitol Health, Regal Funds Management, The Jagen Group, Marubeni Corporation, and Amplify Partners
Other Financing Round (2025): $6.4M, investors not publicly disclosed
Key Investors in Enlitic
Data Collective
Data Collective is a non-profit organization focused on supporting technology that advances the accessibility and understanding of data, providing critical early-stage support for data-centric ventures.
Regal Funds Management
Regal Funds Management is a prominent Australian alternative investment manager known for its expertise in long/short strategies and fundamental research across private and public markets.
Marubeni Corporation
Marubeni Corporation is a diversified Japanese trading and investment conglomerate with a global reach, providing strategic capital and operational expertise across various industrial and technology sectors.
What's next for Enlitic?
With the recent influx of $6.4M, Enlitic is poised to transition into a phase of aggressive market expansion and technological refinement. The strategic focus will likely center on deepening its integration with existing hospital information systems and expanding its regulatory approvals across international markets. As the company scales, it will continue to prioritize the development of its core AI engine, aiming to reduce the cognitive burden on radiologists while maintaining the highest standards of patient safety. The firm's ability to maintain its competitive edge will depend on its capacity to navigate the evolving regulatory landscape while fostering partnerships with major healthcare institutions and diagnostic networks.
See full Enlitic company page
